BR112016006951A2 - novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese - Google Patents

novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese

Info

Publication number
BR112016006951A2
BR112016006951A2 BR112016006951A BR112016006951A BR112016006951A2 BR 112016006951 A2 BR112016006951 A2 BR 112016006951A2 BR 112016006951 A BR112016006951 A BR 112016006951A BR 112016006951 A BR112016006951 A BR 112016006951A BR 112016006951 A2 BR112016006951 A2 BR 112016006951A2
Authority
BR
Brazil
Prior art keywords
prostaglandins
metathesis
new synthesis
synthesis pathways
prostaglandin
Prior art date
Application number
BR112016006951A
Other languages
English (en)
Other versions
BR112016006951B1 (pt
Inventor
Priyapushpa Gamage Chaminda
Viktorovich Arefyev Denis
Petros Yiannikouros George
Kalaritis Panos
Original Assignee
Patheon Api Services Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patheon Api Services Inc filed Critical Patheon Api Services Inc
Publication of BR112016006951A2 publication Critical patent/BR112016006951A2/pt
Publication of BR112016006951B1 publication Critical patent/BR112016006951B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/28—Preparation of ethers by reactions not forming ether-oxygen bonds from acetals, e.g. by dealcoholysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/604—Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)

Abstract

resumo novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese são descritos métodos de síntese de prostaglandinas, análogos de prostaglandina e seus intermediários sintéticos. os métodos podem compreender reações de metátese catalisadas por metal. também são fornecidos intermediários sintéticos que podem ser usados na síntese das prostaglandinas e análogos de prostaglandina.
BR112016006951-0A 2013-09-30 2014-09-30 Novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese BR112016006951B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884656P 2013-09-30 2013-09-30
US61/884,656 2013-09-30
PCT/US2014/058298 WO2015048736A1 (en) 2013-09-30 2014-09-30 Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis

Publications (2)

Publication Number Publication Date
BR112016006951A2 true BR112016006951A2 (pt) 2017-08-01
BR112016006951B1 BR112016006951B1 (pt) 2022-10-04

Family

ID=52744594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006951-0A BR112016006951B1 (pt) 2013-09-30 2014-09-30 Novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese

Country Status (8)

Country Link
US (1) US10100028B2 (pt)
JP (1) JP6488472B2 (pt)
KR (1) KR102311896B1 (pt)
CN (1) CN105592851A (pt)
AU (1) AU2014324499A1 (pt)
BR (1) BR112016006951B1 (pt)
CA (1) CA2925927C (pt)
WO (1) WO2015048736A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
CN112119055A (zh) * 2018-05-15 2020-12-22 加利福尼亚技术学院 通过立体保留性复分解全合成前列腺素j天然产物
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof
US10253011B1 (en) * 2018-07-13 2019-04-09 Chirogate International Inc. Lubiprostone crystals and methods for preparing the same
IL295357A (en) 2020-02-06 2022-10-01 Ocular Therapeutix Inc Preparations and methods for the treatment of eye diseases
TWI805504B (zh) * 2021-08-23 2023-06-11 佳和桂科技股份有限公司 卡前列素緩血酸胺之結晶形式及其製備方法
US20230097470A1 (en) * 2021-08-23 2023-03-30 Chirogate International Inc. Processes and intermediates for the preparations of carboprost and carboprost tromethamine, and carboprost tromethamine prepared therefrom
CN115010692A (zh) * 2022-05-21 2022-09-06 上海彩迩文生化科技有限公司 一类新颖大环内酯的设计、制备及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432950A (en) 1972-11-10 1976-04-22 Ici Ltd Cyclopentane aldehydes as chemical intermediates
US3864387A (en) 1973-05-21 1975-02-04 Upjohn Co 5-Oxa phenyl-and phenoxy-substituted prostaglandin F{HD 1{301 {0 {B analogs
GB1510476A (en) 1975-06-11 1978-05-10 Ici Ltd Stereoselective chemical reduction process for prostaglandin intermediates
US4049678A (en) 1976-03-29 1977-09-20 The Upjohn Company 9-Deoxy-PGD-type, 1,15-lactones
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4049648A (en) 1975-06-23 1977-09-20 The Upjohn Company PG-type, 1,9-lactones
US4116979A (en) 1975-06-23 1978-09-26 Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
USRE30053E (en) 1975-06-23 1979-07-24 The Upjohn Company PG-type, 1,9-lactones
US4033989A (en) 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4201873A (en) 1975-09-17 1980-05-06 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD2 analogs
US4016184A (en) 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4122282A (en) 1975-12-29 1978-10-24 The Upjohn Company 2-Decarboxy-2-carboxyamino-methyl-PGFα compounds
US4032576A (pt) 1976-01-08 1977-06-28
US4055602A (en) 1976-01-08 1977-10-25 The Upjohn Company 2-Decarboxy-2-hydroxy-methyl-5-oxa-17-phenyl-18,19,20-trinor-PGF-analogs
JPS5549372A (en) 1978-10-06 1980-04-09 Res Dev Corp Of Japan Production of macrocyclic lactone
JPS5663979A (en) 1979-10-30 1981-05-30 Teijin Ltd Novel vinyl ether derivative and its preparation
EP0171441A1 (en) 1984-08-10 1986-02-19 Ono Pharmaceutical Co., Ltd. Prostaglandin analogues, processes for their preparation and compositions containing them
EP0386901A1 (en) 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. Novel 5-hetero-6-oxo-PGE derivatives
US5618959A (en) 1995-03-10 1997-04-08 Vivus Incorporated Process for preparing prostaglandin E1, E2 and analogs thereof using furylcopper reagents
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JPH10259179A (ja) 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
DE69821987T2 (de) 1997-12-25 2004-12-16 Ono Pharmaceutical Co. Ltd. Omega-cycloalkyl-prostaglandin e2 derivate
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
JP2003531824A (ja) 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー，インク． フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US6734209B2 (en) 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
KR100437873B1 (ko) 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
NZ532519A (en) 2001-11-05 2006-11-30 Allergan Inc Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
AU2003222049B2 (en) * 2002-03-21 2007-05-31 Cayman Chemical Company, Incorporated Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma
KR100903311B1 (ko) 2002-09-18 2009-06-17 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그를 위한 출발물질
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1707208A4 (en) * 2003-12-05 2010-03-17 Ono Pharmaceutical Co PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL
GB0329379D0 (en) 2003-12-19 2004-01-21 Johnson Matthey Plc Prostaglandin synthesis
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7309799B2 (en) 2004-06-01 2007-12-18 Collegium Pharmaceutical, Inc. Methods for the synthesis of milnacipran and congeners thereof
US20090048203A1 (en) 2004-10-15 2009-02-19 Marta Cavero-Tomas Substituted adenines and the uses thereof
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2007111952A2 (en) 2006-03-22 2007-10-04 The Scripps Research Institute Method of preparing glycopeptides
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
WO2008150302A1 (en) * 2007-06-04 2008-12-11 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with radicicol and its derivatives
AR071312A1 (es) 2008-04-09 2010-06-09 Scinopharm Taiwan Ltd Proceso para la preparacion de analogos de prostaglandina y sus intermediarios
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
KR101045935B1 (ko) 2009-03-11 2011-07-01 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법
EP2413945A1 (en) 2009-04-02 2012-02-08 Colgate-Palmolive Company Oral care compositions comprising tetrapotassium pyrophosphate
EP2454227B1 (en) 2009-07-13 2020-08-19 Patheon API Services Inc. Synthesis of prostanoids
RU2012122367A (ru) 2009-11-05 2013-12-10 Биокон Лимитед Способ получения простагландинов и промежуточные соединения для их получения
IN2013MN00733A (pt) 2010-10-15 2015-06-12 Scinopharm Kunshan Biochemical Technology Co Ltd
US20140114086A1 (en) * 2012-10-22 2014-04-24 The University Of North Carolina At Greensboro Clinprost, Isocarbacyclin And Analogs Thereof And Methods Of Making The Same

Also Published As

Publication number Publication date
BR112016006951B1 (pt) 2022-10-04
CA2925927C (en) 2022-09-06
JP6488472B2 (ja) 2019-03-27
US20160237056A1 (en) 2016-08-18
CN105592851A (zh) 2016-05-18
AU2014324499A1 (en) 2016-05-05
KR20160070772A (ko) 2016-06-20
KR102311896B1 (ko) 2021-10-14
CA2925927A1 (en) 2015-04-02
JP2016533393A (ja) 2016-10-27
WO2015048736A1 (en) 2015-04-02
AU2014324499A8 (en) 2016-05-12
US10100028B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
BR112016006951A2 (pt) novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000298A (es) Reguladores de nrf2
CR20150370A (es) Compuestos antivirales
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2016000145A (es) Reguladores de nrf2
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY34774A (es) Antagonistas del receptor ST2L y métodos de uso
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY34697A (es) Métodos para preparar análogos de nucleótidos
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35500A (es) Indazoles sustituidos con heteroarilo
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
UY35469A (es) Moduladores de p2x7
UY33735A (es) Compuestos antivirales
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
UY34742A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
BR112015021540A2 (pt) processos para a preparação de um agente indutor de apoptose
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2018000182A1 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2014, OBSERVADAS AS CONDICOES LEGAIS